Here's a look at some of the latest news regarding ophthalmic drugs and therapies from the past week.
- Researchers from NeurAegis recently identified an enzyme called calpain-2 that is activated early following increased intraocular pressure, leading researchers to believe developing a calpain-2 inhibitor may be a treatment option for acute glaucoma.
- Earlier this week, Acucela reported top-line results from the Phase 2b/3 clinical trial (S.E.A.T.T.L.E. study) of the investigational visual cycle modulator emixustat hydrochloride (emixustat), stating the study did not meet its primary endpoint with none of the treatment groups showing a significant difference in geographic atrophy (GA) lesion growth rate from placebo.
- Alimera Sciences Limited — the European subsidiary of Alimera Sciences, Inc. — recently announced the availability of real world data showing the majority of diabetic macular edema (DME) patients who received ILUVIEN® (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) in routine clinical practice gained or maintained vision at 12 months.
- Global pharmaceutical company Allergan recently announced the Japanese Ministry of Health, Labour and Welfare has approved an additional use for BOTOX Vista® (Allergan's botulinum toxin type A product) as a treatment for crow's feet lines.